Interaction among abnormal fatty acid oxidation, endothelial function disorder, and oxidative stress in the onset of severe preeclampsia

National Medical Journal of China

Volumn 88, Issue 21, 2008, Pages 1471-1475

  Wang, Jia Lue ^a   Yang, Zi ^a   Wang, Rong ^a   Zhu, Jin Ming ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Eclampsia; Endothelium, vascular; Fatty acid desaturases; Immunohistochamistry; Tumor necrosis factor

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FATTY ACID OXIDATION; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER INJURY; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PROTEIN EXPRESSION;

ADULT; ENDOTHELIUM, VASCULAR; FATTY ACIDS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; OXIDATIVE STRESS; PLACENTA; PPAR GAMMA; PRE-ECLAMPSIA; PREGNANCY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 50249157939     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Llurba E, Casals E, Dominguez C, et al. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism, 2005, 4:1504-1509.
2. Daniel A, Enquobahrie, Michelle A, et al. Maternal Plasma Lipid Concentrations in Early Pregnancy and Risk of Preeclampsia. Am J Hypertens, 2004, 17:574-581.
3. Bayhan G, Kocyigit Y, Atamer A, et al. Potential atherogenic roles of lipids, lipopretein (a) and lipid peroxidation in preeclampsia. Gynecol Endocrinol, 2005, 21:1-6.
4. Chinese source.
5. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med, 1999, 340:1723-1731.
6. Ibdah JA, Yang Zi, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Molecular Genetics Metabolism, 2000, 71: 182-189.
7. von Dadelszen P, Magee LA, Roberts JM. Subclassification of Preeclampsia. Hypertension Pregnancy, 2003, 22: 143-148.
8. Zhang WY, Schwartz E, Wang Y, et al. Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol, 2006, 26:514-519.
9. Oprescu AI, Bikopoulos G, Naassan A, et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes, 2007, 56:2927-2937.
10. Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappa B Pathway in rat liver. Diabetes, 2005, 54:3458-3465.
11. Osman MM, Osman KA, Ahmed MH. et al. Abnormal glucose tolerance and non-esterified fatty acids (NEFAs) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH. J Clin Gastroenterol, 2007, 41:118-119.
12. Artwohl M, Roden M, Waldhäusl W, et al. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J, 2004, 18:146-148.
13. Chinese source.
14. Matern D, Shehata BM, Shekhawat P, et al. Placental Floor Infarction Complicating the Pregnancy of a Fetus with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) Deficiency. Molecular Genetics Metabolism, 2001, 72: 265-268.
15. Sasaki M, Jordan P, Welbourne T, et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol, 2005, 5:3.
16. Awara WM, el-Sisi AE, el-Refaei M, et al. Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes. Rev Diabet Stud, 2005, 2:146-156.
17. Martens FM, Rabelink TJ, op't Roodt J, et al. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J, 2006, 27: 1605-1609.
18. Pasceri V, Wu HD, Willerson JT, et al. Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator-Activated Reeeptor-γ Activators, Circulation, 2000, 101: 235-238.
19. Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator activated receptor- α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol, 2003, 23:45-51.
20. Mehta JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol, 2003, 23:2203-2208.
21. Motojima K, Passilly P, Peters JM, et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem, 1998, 273: 16710-16714.
22. Egbor M, Ansari T, Morris N, et al. Morphometrie placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG, 2006, 113: 580-589.
23. Rodie VA, Young A, Jordan F, et al. Human placental peroxisome proliferator-activated receptor and expression in healthy pregnancy and in preeclampsia and intrauterine growth restriction. J Soc Gyneeol Investig, 2005, 12:320-329.